SGRY
Surgery Partners Inc
14.20$
-2.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.4% | +1.4% | +7.4% | +0.6% | +4.7% | +0.8% | +0.1% | -0.1% | +3.7% | -2.4% | +0.1% | |
| – | +2.1% | +0.1% | +13.0% | +2.3% | +8.1% | -4.0% | +2.9% | -0.3% | +4.4% | -5.9% | +4.0% | |
| – | -17.0% | -5.5% | +15.3% | +3.9% | +21.5% | -14.9% | +9.1% | -18.7% | +17.9% | -24.0% | +18.9% | |
| – | -17.0% | -5.5% | +15.3% | +3.9% | +21.5% | -14.9% | +9.1% | -18.7% | +17.9% | -24.0% | +18.9% | |
| – | +7.3% | -0.4% | +5.9% | +3.7% | +6.7% | -1.5% | -1.3% | +2.9% | +4.0% | +0.2% | +2.2% | |
| – | +8.4% | +2.4% | +5.1% | +1.4% | +7.8% | -0.3% | -0.9% | +5.7% | +4.7% | +4.0% | -1.7% | |
| – | +1.9% | +1.7% | +9.3% | +0.2% | +5.2% | +1.1% | -0.5% | -0.1% | +2.0% | +0.2% | – | |
| – | -2.0% | -2.2% | -2.6% | -11.7% | -0.9% | -1.1% | -8.4% | +3.9% | -4.7% | -2.9% | +13,071.1% | |
| – | +1.5% | +2.8% | +7.1% | +3.0% | +6.7% | +2.5% | +0.3% | +0.4% | +7.3% | -3.3% | +8.5% | |
| – | +4.3% | +0.1% | +5.4% | +4.2% | +8.6% | -8.8% | +0.7% | +2.2% | +5.0% | -5.5% | -0.6% | |
| – | +13.4% | +3.7% | +14.5% | +5.3% | +2.7% | +0.8% | +4.3% | -3.5% | -1.6% | +0.4% | -27.8% | |
| – | +15.5% | +1.3% | -0.1% | -1.8% | +22.2% | -20.9% | +6.0% | -0.2% | +19.5% | -19.2% | +3.9% | |
| – | +2.3% | +3.4% | +8.8% | +1.8% | +5.6% | +5.4% | +0.5% | -0.1% | +4.1% | +0.3% | +1.0% | |
| – | -0.9% | -1.0% | -0.8% | -2.9% | -5.6% | -2.8% | +0.5% | -1.1% | -1.0% | -1.5% | -1.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.2% | +0.1% | +0.0% | +0.0% | +0.3% | +0.3% | 0.0% | +0.2% | +0.9% | +0.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.